LCMT1

Summary

LCMT1 (leucine carboxyl methyltransferase 1, HGNC:17557) is a protein-coding gene on chromosome 16p12.1, encoding Leucine carboxyl methyltransferase 1 (Q9UIC8). Methylates the carboxyl group of the C-terminal leucine residue of protein phosphatase 2A catalytic subunits to form alpha-leucine ester residues. It is a selective cancer dependency (DepMap: 31.1% of cell lines).

LCMT1 catalyzes the methylation of the carboxyl group of the C-terminal leucine residue (leu309) of the catalytic subunit of protein phosphatase-2A (PPP2CA; MIM 176915) (De Baere et al., 1999 [PubMed 10600115]).

Source: NCBI Gene 51451 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 68 total
• Cancer dependency (DepMap): dependent in 31.1% of screened cell lines
• MANE Select transcript: NM_016309

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17557
Approved symbol	LCMT1
Name	leucine carboxyl methyltransferase 1
Location	16p12.1
Locus type	gene with protein product
Status	Approved
Aliases	CGI-68, PPMT1
Ensembl gene	ENSG00000205629
Ensembl biotype	protein_coding
OMIM	610286
Entrez	51451

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 10 protein_coding, 3 nonsense_mediated_decay, 3 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000380962, ENST00000380966, ENST00000399069, ENST00000564011, ENST00000570981, ENST00000572761, ENST00000572869, ENST00000573435, ENST00000574450, ENST00000575396, ENST00000576382, ENST00000576625, ENST00000577157, ENST00000892900, ENST00000918761, ENST00000918762, ENST00000918763, ENST00000949527

RefSeq mRNA: 2 — MANE Select: NM_016309 NM_001032391, NM_016309

CCDS: CCDS45445, CCDS45446

Canonical transcript exons

ENST00000399069 — 11 exons

Exon	Start	End
ENSE00001487012	25111742	25111996
ENSE00003492317	25174937	25175034
ENSE00003546735	25170714	25170805
ENSE00003547727	25164598	25164718
ENSE00003555731	25161102	25161204
ENSE00003559956	25128475	25128566
ENSE00003559964	25169112	25169213
ENSE00003571132	25151554	25151615
ENSE00003640017	25140171	25140247
ENSE00003674688	25132402	25132523
ENSE00003690310	25178001	25178228

Expression profiles

Bgee: expression breadth ubiquitous, 285 present calls, max score 96.49.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 32.6911 / max 165.9154, expressed in 1817 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
153266	18.4902	1809
153267	13.4836	1787
153265	0.5800	328
153268	0.1373	65

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	96.49	gold quality
body of pancreas	UBERON:0001150	95.22	gold quality
prefrontal cortex	UBERON:0000451	95.18	gold quality
oocyte	CL:0000023	94.98	gold quality
nucleus accumbens	UBERON:0001882	94.98	gold quality
cortical plate	UBERON:0005343	94.84	gold quality
right frontal lobe	UBERON:0002810	94.83	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	94.80	gold quality
pons	UBERON:0000988	94.70	gold quality
Brodmann (1909) area 23	UBERON:0013554	94.65	gold quality
anterior cingulate cortex	UBERON:0009835	94.63	gold quality
cingulate cortex	UBERON:0003027	94.60	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	94.51	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.45	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.43	gold quality
primary visual cortex	UBERON:0002436	94.27	gold quality
neocortex	UBERON:0001950	94.20	gold quality
frontal cortex	UBERON:0001870	94.17	gold quality
ganglionic eminence	UBERON:0004023	94.14	gold quality
amygdala	UBERON:0001876	94.02	gold quality
pancreas	UBERON:0001264	93.97	gold quality
adrenal tissue	UBERON:0018303	93.93	gold quality
caudate nucleus	UBERON:0001873	93.90	gold quality
cerebellar vermis	UBERON:0004720	93.82	gold quality
cerebellar cortex	UBERON:0002129	93.80	gold quality
adenohypophysis	UBERON:0002196	93.80	gold quality
cerebellar hemisphere	UBERON:0002245	93.78	gold quality
mucosa of transverse colon	UBERON:0004991	93.68	gold quality
cerebellum	UBERON:0002037	93.66	gold quality
muscle of leg	UBERON:0001383	93.61	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-6058	no	361.04
E-HCAD-5	no	2.40
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

9 targeting LCMT1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-513C-5P	99.50	68.42	1730
HSA-MIR-514B-5P	99.50	68.19	1766
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-505-3P	99.19	69.71	896
HSA-MIR-6815-3P	99.13	68.98	1530
HSA-MIR-873-5P	98.84	66.90	1348
HSA-MIR-3928-3P	97.61	66.53	1096
HSA-MIR-4654	95.86	65.72	751

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 31.1% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 9)

• LCMT-1 is important for normal progression through mitosis and cell survival and is essential for embryonic development (PMID:17724024)
• X-ray crystal structure of human LCMT1 protein in complex with the cofactor S-adenosylmethionine (AdoMet) has been solved to a resolution of 2 A. (PMID:21206058)
• determined crystal structures of human LCMT-1 in isolation and in complex with PP2A stabilized by a cofactor mimic. The structures show that the LCMT-1 active-site pocket recognizes the carboxyl terminus of PP2A (PMID:21292165)
• Data indicate that PP2A holoenzyme biogenesis and activity are controlled by five PP2A modulators, consisting of alpha4, PTPA, LCMT1, PME-1 and TIPRL1, which serve to prevent promiscuous phosphatase activity until the holoenzyme is completely assembled. (PMID:22443683)
• GSK-3beta can inhibit PP2A by increasing the inhibitory L309-demethylation involving upregulation of PME-1 and inhibition of PPMT1 (PMID:22732552)
• alterations in the membrane localization of PP2A and Tau following down-regulation of LCMT1 may lead to PP2A and Tau dysfunction in AD. (PMID:23943618)
• LCMT1-PME-1 methylation equilibrium is critical for regulating mitotic spindle size and thereby proper cell division (PMID:25839665)
• We demonstrate that NNMT outcompetes leucine carboxyl methyl transferase 1 (LCMT1) for methyl transfer from principal methyl donor SAM in biological systems. Inhibiting NNMT increased the availability of methyl groups for LCMT1 to methylate PP2A, resulting in the inhibition of oncogenic serine/threonine kinases (STK). (PMID:27810903)
• Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance. (PMID:37644036)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	lcmt1	ENSDARG00000045140
mus_musculus	Lcmt1	ENSMUSG00000030763
rattus_norvegicus	Lcmt1	ENSRNOG00000014565
drosophila_melanogaster	CG3793	FBGN0028507
caenorhabditis_elegans		WBGENE00007137

Paralogs (1): LCMT2 (ENSG00000168806)

Protein

Protein identifiers

Leucine carboxyl methyltransferase 1 — Q9UIC8 (reviewed: Q9UIC8)

Alternative names: Protein-leucine O-methyltransferase, [Phosphatase 2A protein]-leucine-carboxy methyltransferase 1

All UniProt accessions (7): Q9UIC8, H3BUP7, H7BYF0, I3L2E3, I3L2Q8, I3L4A2, I3L537

UniProt curated annotations — full annotation on UniProt →

Function. Methylates the carboxyl group of the C-terminal leucine residue of protein phosphatase 2A catalytic subunits to form alpha-leucine ester residues.

Similarity. Belongs to the methyltransferase superfamily. LCMT family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9UIC8-1	1	yes
Q9UIC8-2	2
Q9UIC8-3	3

RefSeq proteins (2): NP_001027563, NP_057393* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007213	Ppm1/Ppm2/Tcmp	Family
IPR016651	LCMT1	Family
IPR029063	SAM-dependent_MTases_sf	Homologous_superfamily

Pfam: PF04072

Enzyme classification (BRENDA):

• EC 2.1.1.233 — [phosphatase 2A protein]-leucine-carboxy methyltransferase (BRENDA: 8 organisms, 14 substrates, 2 inhibitors, 1 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

1 substrates with measured Km, best-characterized 1. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
[PHOSPHATASE 2A PROTEIN]-LEUCINE	0.0018	1

Catalyzed reactions (Rhea), 1 shown:

• [phosphatase 2A protein]-C-terminal L-leucine + S-adenosyl-L-methionine = [phosphatase 2A protein]-C-terminal L-leucine methyl ester + S-adenosyl-L-homocysteine (RHEA:48544)

UniProt features (45 total): helix 16, strand 9, sequence conflict 7, binding site 6, turn 4, splice variant 2, chain 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
3IEI	X-RAY DIFFRACTION	1.9
3O7W	X-RAY DIFFRACTION	2
3P71	X-RAY DIFFRACTION	2.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UIC8-F1	93.80	0.90

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (6): 37; 73; 98; 122; 171–172; 198

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-69273	Cyclin A/B1/B2 associated events during G2/M transition
R-HSA-1640170	Cell Cycle
R-HSA-453274	Mitotic G2-G2/M phases
R-HSA-69275	G2/M Transition
R-HSA-69278	Cell Cycle, Mitotic

MSigDB gene sets: 177 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY, GOBP_CHROMOSOME_ORGANIZATION, GOBP_REGULATION_OF_CELL_CYCLE_CHECKPOINT, GOBP_REGULATION_OF_NUCLEAR_DIVISION, GOBP_CELL_CYCLE_PHASE_TRANSITION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, MODULE_493, GOBP_CHROMOSOME_SEPARATION, CREBP1_Q2, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, HUMMERICH_SKIN_CANCER_PROGRESSION_DN, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A5, KEGG_HISTIDINE_METABOLISM

GO Biological Process (10): G2/M transition of mitotic cell cycle (GO:0000086), protein methylation (GO:0006479), C-terminal protein methylation (GO:0006481), regulation of glucose metabolic process (GO:0010906), negative regulation of protein-containing complex assembly (GO:0031333), protein modification process (GO:0036211), regulation of apoptotic process (GO:0042981), regulation of mitotic cell cycle spindle assembly checkpoint (GO:0090266), regulation of signal transduction (GO:0009966), methylation (GO:0032259)

GO Molecular Function (7): protein C-terminal carboxyl O-methyltransferase activity (GO:0003880), S-adenosylmethionine-dependent methyltransferase activity (GO:0008757), protein C-terminal leucine carboxyl O-methyltransferase activity (GO:0018423), protein binding (GO:0005515), methyltransferase activity (GO:0008168), protein methyltransferase activity (GO:0008276), transferase activity (GO:0016740)

GO Cellular Component (2): nucleoplasm (GO:0005654), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
G2/M Transition	1
Cell Cycle, Mitotic	1
Mitotic G2-G2/M phases	1
Cell Cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
methyltransferase activity	2
cellular anatomical structure	2
mitotic cell cycle	1
mitotic cell cycle phase transition	1
cell cycle G2/M phase transition	1
protein alkylation	1
macromolecule methylation	1
protein methylation	1
C-terminal protein amino acid modification	1
glucose metabolic process	1
regulation of carbohydrate metabolic process	1
regulation of small molecule metabolic process	1
regulation of protein-containing complex assembly	1
negative regulation of cellular component organization	1
protein-containing complex assembly	1
protein metabolic process	1
macromolecule modification	1
apoptotic process	1
regulation of programmed cell death	1
regulation of mitotic nuclear division	1
mitotic spindle assembly checkpoint signaling	1
regulation of mitotic sister chromatid separation	1
regulation of mitotic metaphase/anaphase transition	1
regulation of mitotic sister chromatid segregation	1
regulation of mitotic spindle checkpoint	1
signal transduction	1
regulation of cell communication	1
regulation of signaling	1
regulation of response to stimulus	1
metabolic process	1
protein carboxyl O-methyltransferase activity	1
protein C-terminal carboxyl O-methyltransferase activity	1
S-adenosylmethionine-dependent methyltransferase activity	1
binding	1
transferase activity, transferring one-carbon groups	1
catalytic activity, acting on a protein	1
catalytic activity	1
nuclear lumen	1
cytoplasm	1

Protein interactions and networks

STRING

1028 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LCMT1	PPP2R2A	P50409	965
LCMT1	PPP2CA	P05323	931
LCMT1	PPME1	Q9Y570	915
LCMT1	PTPA	Q15257	744
LCMT1	TIPRL	O75663	710
LCMT1	PPP2R1A	P30153	608
LCMT1	PPP4C	P33172	589
LCMT1	PPP2R3B	Q9Y5P8	586
LCMT1	PPP2R3A	Q06190	585
LCMT1	NPRL3	Q12980	569
LCMT1	PPP2R5A	Q15172	565
LCMT1	AQP8	O94778	550
LCMT1	PPP2R5D	Q14738	539
LCMT1	NPRL2	Q8WTW4	531
LCMT1	MINK1	Q8N4C8	527

IntAct

12 interactions, top by confidence:

A	B	Type	Score
FXR2	LCMT1	psi-mi:“MI:0915”(physical association)	0.510
LCMT1	FXR2	psi-mi:“MI:0915”(physical association)	0.510
PPP2CA	LCMT1	psi-mi:“MI:0915”(physical association)	0.400
LCMT1	VPS37C	psi-mi:“MI:0915”(physical association)	0.400
CFTR	LCMT1	psi-mi:“MI:0915”(physical association)	0.370
LCMT1	TAB1	psi-mi:“MI:0915”(physical association)	0.370
LCMT1	PPP4C	psi-mi:“MI:0914”(association)	0.350
DND1	HNRNPCL1	psi-mi:“MI:0914”(association)	0.350
TGDS	GPD1	psi-mi:“MI:0914”(association)	0.350
LCMT1	solA	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (35): PPP2CA (Affinity Capture-MS), PPP4C (Affinity Capture-MS), EIF1AX (Affinity Capture-MS), PPP4R2 (Affinity Capture-MS), LCMT1 (Two-hybrid), LCMT1 (Affinity Capture-Western), LCMT1 (Co-fractionation), NECAP1 (Co-fractionation), TANGO2 (Co-fractionation), PPP2CA (Affinity Capture-MS), PPP4R2 (Affinity Capture-MS), PPP4C (Affinity Capture-MS), LCMT1 (Affinity Capture-MS), LCMT1 (Negative Genetic), LCMT1 (Negative Genetic)

ESM2 similar proteins: A2AV36, A2VD33, A4QN59, A4QP75, A6QQV6, B0WSX1, B3MZN7, B4PYH5, B8A5G9, D3ZG52, D9IVE5, E1BMP7, F1QCV2, O95470, P51530, Q14CH1, Q16GH0, Q16P90, Q28CZ7, Q2VPA6, Q32PX9, Q3T0H0, Q3TZM9, Q4KLT3, Q4V7D6, Q502I6, Q58E95, Q5U4E8, Q5U534, Q5ZIB9, Q5ZKG3, Q655R6, Q6NTR1, Q6P4Z6, Q6PCI6, Q6ZQJ5, Q8AWD2, Q8BIP0, Q8GWT4, Q8LGM7

Diamond homologs: O60294, O94257, P0CO56, P0CO57, P46554, Q3T0H0, Q4ICG8, Q4WS57, Q5AQJ2, Q5XIA3, Q5Z8K3, Q60YU0, Q6C997, Q6P4Z6, Q75AW4, Q8BYR1, Q8VY08, Q9UIC8, Q6BQD2, Q7SAP7, Q4P4G2, Q9P3K9, Q5A387, Q6FUI5, Q04081, Q6CWW0, Q759U5, O60157, Q08282, Q5A931, Q6FXA5, A1KGK7, A5U0B2, P9WFI6, P9WFI7, Q7U1E6, Q9LR78, Q2U6D4, Q4WVD1, Q5BH52

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
LCMT1	“up-regulates activity”	PPP2CA	methylation
LCMT1	“up-regulates activity”	PPP2CB	methylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

68 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	48
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2117 predictions. Top by Δscore:

Variant	Effect	Δscore
16:25161170:G:GT	donor_gain	1.0000
16:25161179:C:G	donor_gain	1.0000
16:25161184:GAAAT:G	donor_gain	1.0000
16:25161205:G:GG	donor_gain	1.0000
16:25164596:A:G	acceptor_gain	1.0000
16:25164726:G:GT	donor_gain	1.0000
16:25169106:TCCTA:T	acceptor_loss	1.0000
16:25169107:CCTAG:C	acceptor_loss	1.0000
16:25169108:CTAGG:C	acceptor_loss	1.0000
16:25169109:TAGGT:T	acceptor_loss	1.0000
16:25169110:A:AG	acceptor_gain	1.0000
16:25169110:AGG:A	acceptor_loss	1.0000
16:25169111:G:GG	acceptor_gain	1.0000
16:25169195:C:T	donor_gain	1.0000
16:25169209:CACAG:C	donor_loss	1.0000
16:25169211:CAGG:C	donor_loss	1.0000
16:25169212:AG:A	donor_loss	1.0000
16:25169213:GGTC:G	donor_loss	1.0000
16:25169214:G:A	donor_loss	1.0000
16:25169215:T:A	donor_loss	1.0000
16:25170706:C:G	acceptor_gain	1.0000
16:25174936:GGATA:G	acceptor_gain	1.0000
16:25175020:G:GT	donor_gain	1.0000
16:25175023:GAAA:G	donor_gain	1.0000
16:25175024:A:T	donor_gain	1.0000
16:25175030:GCTTG:G	donor_gain	1.0000
16:25175031:C:G	donor_gain	1.0000
16:25175033:TGG:T	donor_loss	1.0000
16:25175035:G:GG	donor_gain	1.0000
16:25175036:T:A	donor_loss	1.0000

AlphaMissense

2198 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:25169130:T:C	F237L	0.999
16:25169132:T:A	F237L	0.999
16:25169132:T:G	F237L	0.999
16:25174963:A:T	E304V	0.999
16:25111994:G:C	K37N	0.998
16:25111994:G:T	K37N	0.998
16:25132512:T:A	W106R	0.998
16:25132512:T:C	W106R	0.998
16:25169155:T:C	L245P	0.998
16:25128480:C:A	A40E	0.997
16:25128565:A:C	R68S	0.997
16:25128565:A:T	R68S	0.997
16:25140207:G:C	D122H	0.997
16:25164621:A:T	E198V	0.997
16:25164625:T:G	C199W	0.997
16:25169131:T:G	F237C	0.997
16:25170738:T:A	W273R	0.997
16:25170738:T:C	W273R	0.997
16:25128558:T:C	I66T	0.996
16:25132402:G:A	G69E	0.996
16:25132411:C:A	A72D	0.996
16:25132500:G:C	D102H	0.996
16:25140208:A:T	D122V	0.996
16:25140233:G:C	K130N	0.996
16:25140233:G:T	K130N	0.996
16:25161153:G:C	R173P	0.996
16:25164635:T:C	Y203H	0.996
16:25169143:T:C	M241T	0.996
16:25169144:G:A	M241I	0.996
16:25169144:G:C	M241I	0.996

dbSNP variants (sampled 300 via entrez): RS1000013234 (16:25151616 G>A), RS1000061360 (16:25151841 C>T), RS1000113500 (16:25152147 G>T), RS1000115938 (16:25137827 T>G), RS1000144007 (16:25135527 G>A,T), RS1000229257 (16:25168113 A>G,T), RS1000239972 (16:25129415 G>A), RS1000242131 (16:25130166 C>T), RS1000269995 (16:25168382 A>G), RS1000294471 (16:25130302 T>C), RS1000361347 (16:25157533 G>A), RS1000471202 (16:25112990 T>C), RS1000523348 (16:25146341 A>C,G,T), RS1000554747 (16:25147987 G>A), RS1000570823 (16:25173974 C>T)

Disease associations

OMIM: gene MIM:610286 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002935_23	Lead levels	8.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects methylation, decreases expression, increases abundance, increases expression	4
Arsenic	decreases expression, increases abundance, increases expression	2
Valproic Acid	affects expression, increases expression	2
Cyclosporine	increases expression	2
aristolochic acid I	increases expression	1
GSK-J4	increases expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
bisphenol A	affects cotreatment, decreases methylation	1
trichostatin A	affects expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
bisphenol S	increases methylation	1
Temozolomide	decreases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Acetaminophen	increases expression	1
Acrolein	increases abundance, affects cotreatment, increases oxidation	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Arecoline	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Carbamazepine	affects expression	1
Ozone	affects cotreatment, increases oxidation, increases abundance	1
Nocodazole	decreases response to substance	1
Aflatoxin B1	decreases methylation	1
Sodium Selenite	increases expression	1
Okadaic Acid	increases expression	1
Lactic Acid	decreases expression	1
Volatile Organic Compounds	affects cotreatment, increases oxidation	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SV37	HAP1 LCMT1 (-) 1	Cancer cell line	Male
CVCL_SV38	HAP1 LCMT1 (-) 2	Cancer cell line	Male
CVCL_SV39	HAP1 LCMT1 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.